Every prototype, every test, every iteration in your engineering process may already qualify.
Medical device development means solving problems with no predetermined answer, iterating on materials, geometries, and processes, testing and redesigning dozens of times before a device reaches a patient. Yet many device companies see R&D tax credits as a pharma-only benefit, missing one of the most defensible claims in life sciences.
A Credit Built for This Work
IRC §41(d)’s Four-Part Test – permitted purpose, technical uncertainty, experimentation, and technological basis – rewards exactly this kind of iterative engineering. Medical device companies are often in a stronger position to claim than pharma, because design controls already document the iteration thoroughly. The FDA-required Design History File (DHF) can double as a roadmap of qualifying activity.
Where Uncertainty Shows Up
Uncertainty is woven into nearly every design decision:
- Balancing biocompatibility, durability, and manufacturability in material selection
- Hitting mechanical performance targets (fatigue life, tensile strength) under miniaturization constraints
- Confirming sterilization method (EtO, gamma, autoclave) doesn’t degrade function
- Designing for manufacturability at scale without losing tolerances
- Integrating sensors, firmware, or connectivity for combination/digital devices
Each is a point where engineers must test and iterate, not just look up the answer.
The Four-Part Test in Medical Device Engineering
- Permitted Purpose: improving function, performance, reliability, or quality (e.g., a new catheter delivery mechanism or better implant wear resistance)
- Uncertainty: genuine technical unknowns, like whether a design change meets ISO 10993 biocompatibility without new toxicology concerns
- Experimentation: iterative bench testing, FEA, and DOE across prototype revisions
- Technological in Nature: grounded in materials science, mechanical/biomedical engineering, human factors science
Qualifying Activities Across the Lifecycle
- Design & Prototyping: CAD iteration, rapid prototyping/3D printing, design FMEA
- Verification & Validation: bench testing, simulated use testing, accelerated aging studies
- Human Factors/Usability: formative and summative testing to reduce use error
- Biocompatibility & Sterilization: iterative method selection and validation
- Software/Firmware: algorithm development, embedded systems debugging (for connected devices)
What Doesn’t Qualify
- Routine QA/QC on an already-validated design
- Regulatory submission writing itself (510(k)/PMA) – though the underlying testing behind it does
- Post-market surveillance data collection without an accompanying design change
Qualified Research Expenses (QREs)
- Wages of engineers, R&D technicians, and QA/regulatory staff supporting testing
- Supplies – materials, tooling, test fixtures used in prototyping and testing
- Contract research – outside test labs/CROs for biocompatibility or sterilization validation
Note: capital equipment generally doesn’t qualify; cloud/software costs may, for connected devices.
Documentation: A Built-In Advantage
Design Controls under 21 CFR 820.30 already require documenting design inputs/outputs, V&V records, and risk analysis, captured in the DHF. That’s largely the same evidence needed to substantiate an R&D credit claim. FDA rigor and IRS documentation requirements overlap substantially.
Bottom Line
If your team is investing in design iteration, prototyping, or verification and validation testing, it’s worth finding out whether that work qualifies. Leyton offers an assessment to help medical device companies identify and substantiate their R&D tax credit opportunity.